Evidence map›Paper›PMID 27042088›Full record

ReviewBreast cancer : basic and clinical research2016

A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer.

Simon B Zeichner, Hiromi Terawaki, Keerthi Gogineni

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Breast cancer : basic and clinical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 2 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 2 syntheses or guidelines pooled it, 198 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. A non-inferiority, phase III trial of gemcitabine plus capecitabineTherapeutic advances in medical oncology · 2024
    Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Simon B ZeichnerDepartment of Hematology & Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Hiromi TerawakiDepartment of Hematology & Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Keerthi GogineniDepartment of Hematology & Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Emory University · US

Funding

Translational Physician-Scientist Training Program in OncologyT32CA160040 · NCI · EMORY UNIVERSITY · PI SHIN, DONG M · 2013 to 2017
$1.2M
NCI NIH HHS T32 CA160040
6 · The paper itself

Abstract

Patients with breast cancer along with metastatic estrogen and progesterone receptor (ER/PR)- and human epidermal growth factor receptor 2 (HER2)-negative tumors are referred to as having metastatic triple-negative breast cancer (mTNBC) disease. Although there have been many new treatment options approved by the Food and Drug Administration for ER/PR-positive and Her2/neu-amplified metastatic breast cancer, relatively few new agents have been approved for patients with mTNBC. There have been several head-to-head chemotherapy trials performed within the metastatic setting, and much of what is applied in clinical practice is extrapolated from chemotherapy trials in the adjuvant setting, with taxanes and anthracyclines incorporated early on in the patient's treatment course. Select synergistic combinations can produce faster and more significant response rates compared with monotherapy and are typically used in the setting of visceral threat or symptomatic disease. Preclinical studies have implicated other possible targets and mechanisms in mTNBC. Ongoing clinical trials are underway assessing new chemotherapeutic strategies and agents, including targeted therapy and immunotherapy. In this review, we evaluate the standard systemic and future treatment options in mTNBC.

Indexed as

hormone receptor-negative breast cancermetastatic breast cancertriple-negative breast cancer

Identifiers

PMID27042088
PMCPMC4807882
OpenAlexW2308070604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.